Prostate cancer – Advantages and disadvantages of MR-guided RT

EU. Epidemiology of prostate cancer in Europe [Internet]. EU science hub. Available from: https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe. Dearnaley, 2007, Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial, Lancet Oncol. [Internet], 8, 475, 10.1016/S1470-2045(07)70143-2 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol., 17, 1047, 10.1016/S1470-2045(16)30102-4 Catton, 2017, Trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, Int. J. Clin. Oncol., 35, 1884, 10.1200/JCO.2016.71.7397 Gulliford, 2010, Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397, Int J Radiat Oncol Biol Phys [Internet], 76, 747, 10.1016/j.ijrobp.2009.02.025 Deegan, 2015, Assessment of cone beam CT registration for prostate radiation therapy: fiducial marker and soft tissue methods, J. Med. Imaging Radiat. Oncol., 59, 91, 10.1111/1754-9485.12197 Mottet, 2017, Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur. Urol., 71, 618, 10.1016/j.eururo.2016.08.003 Henderson, 2018, Dosimetric implications of computerised tomography-only versus magnetic resonance-fusion contouring in stereotactic body radiotherapy for prostate cancer, Medicines, 5, 32, 10.3390/medicines5020032 Pathmanathan, 2019, Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI, Radiat. Oncol. Phys. Salembier, 2018, ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer, Radiother. Oncol., 127, 49, 10.1016/j.radonc.2018.01.014 Kerkmeijer, 2018, Magnetic resonance imaging only workflow for radiotherapy simulation and planning in prostate cancer, Oncology, 30, 692 Langen, 2008, Observations on real-time prostate gland motion using electromagnetic tracking, Int. J. Radiat. Oncol. Biol. Phys. [Internet], 71, 1084, 10.1016/j.ijrobp.2007.11.054 Curtis, 2013, Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data, Int. J. Radiat. Oncol. Biol. Phys. [Internet], 85, 700, 10.1016/j.ijrobp.2012.05.044 de, 2019, Fiducial marker based intra-fraction motion assessment on cine-MR for MR-Linac treatment of prostate cancer, Phys. Med. Biol. Tetar, 2019, Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer, Phys. Imaging Radiat. Oncol., 9, 69, 10.1016/j.phro.2019.02.002 Winkel, D., Bol, G.H., Kroon, P.S., van Asselen, B., Hackett, S.S., Werensteijn-Honingh, A.M., et al. Adaptive radiotherapy: The Elkta Unity MR-linac concept. Clinical and Translational Radiation Oncology. http://dx.doi.org/10.1016/j.ctrol.2019.04.001. Klüter, S. Technical design and concept of a 0.35 T MR-Linac. Clinical and Translational Radiation Oncology. http://dx.doi.org/10.1016/j.ctro.2019.03.005. Fischer-valuck, 2017, Two-and-a-half-year clinical experience with the world’s first magnetic resonance image guided radiation therapy system, Adv. Radiat. Oncol. [Internet], 2, 485, 10.1016/j.adro.2017.05.006 Pathmanathan, 2019, Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy, Br. J. Radiol., 92 Lips, 2011, Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial, Trials [Internet], 12, 255, 10.1186/1745-6215-12-255 Monninkhof, 2018, Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial, Radiother. Oncol. [Internet], 127, 74, 10.1016/j.radonc.2017.12.022 Onjukka, 2017, Twenty fraction prostate radiotherapy with intra-prostatic boost: results of a pilot study, Clin. Oncol. [Internet], 29, 6, 10.1016/j.clon.2016.09.009 Hotker, 2016, Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative multi-parametric MRI, Eur. Radiol., 25, 2665, 10.1007/s00330-015-3688-1 Groenendaal, 2012, The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy, Radiother. Oncol. [Internet], 103, 233, 10.1016/j.radonc.2011.12.007 Lee, 2016, Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J. Clin. Oncol. [Internet], 34, 2325, 10.1200/JCO.2016.67.0448 Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol., 17, 1061, 10.1016/S1470-2045(16)30070-5 Hoskin, 2017, Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer, Radiother. Oncol. [Internet], 124, 56, 10.1016/j.radonc.2017.06.014 Krauss, 2017, Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy, Int. J. Radiat. Oncol. [Internet], 97, 98, 10.1016/j.ijrobp.2016.08.011 Prada, 2018, High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results, Int. J. Radiat. Oncol. Biol. Phys., 17, 845 Siddiqui, 2019, Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer, Radiat. Oncol. Biol. [Internet], 248, 1